<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; Amylin Pharmaceuticals</title>
	<atom:link href="http://www.rxtimes.com/tag/amylin-pharmaceuticals/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>BYDUREON(TM) Reply Submitted to FDA</title>
		<link>http://www.rxtimes.com/bydureontm-reply-submitted-to-fda/</link>
		<comments>http://www.rxtimes.com/bydureontm-reply-submitted-to-fda/#comments</comments>
		<pubDate>Thu, 28 Jul 2011 21:19:38 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Amylin Pharmaceuticals]]></category>
		<category><![CDATA[BYETTA®]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[exenatide]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5365</guid>
		<description><![CDATA[SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., &#8211; Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/bydureontm-reply-submitted-to-fda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission</title>
		<link>http://www.rxtimes.com/amylin-lilly-and-alkermes-receive-complete-response-letter-from-fda-for-exenatide-once-weekly-submission/</link>
		<comments>http://www.rxtimes.com/amylin-lilly-and-alkermes-receive-complete-response-letter-from-fda-for-exenatide-once-weekly-submission/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 12:17:54 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[Amylin Pharmaceuticals]]></category>
		<category><![CDATA[Bydureon]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[Lilly]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=4622</guid>
		<description><![CDATA[SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension). In [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/amylin-lilly-and-alkermes-receive-complete-response-letter-from-fda-for-exenatide-once-weekly-submission/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

